Name: VERACYTE INC (VCYT) Stock
Brand: VERACYTE INC
Rating: 7.5 (3 reviews)

VCYT Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill

Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price

3 days ago - By: Zacks Investment Research - Mentions: ISRG PLSE AORT

PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor

3 days ago - By: Zacks Investment Research - Mentions: ISRG COR MEDP

Here's Why You Should Add Cencora Stock to Your Portfolio Now

5 days ago - By: Zacks Investment Research - Mentions: LVS MMM KO AMGN ...

Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus

10 days ago - By: Zacks Investment Research - Mentions: UHS EHC BTSG

EHC Opens New Lake Worth Rehab Hospital to Meet Rising Demand

11 days ago - By: Zacks Investment Research

Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term

24 days ago - By: Zacks Investment Research - Mentions: UHS TDOC BTSG

TDOC Partners With TytoCare to Expand At-Home Exam Capabilities

a month ago - By: Zacks Investment Research - Mentions: UHS EXAS ENSG

Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat

a month ago - By: Zacks Investment Research - Mentions: UHS EXAS EHC

Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat

a month ago - By: Zacks Investment Research - Mentions: BSX IDXX MEDP

VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up

a month ago - By: Zacks Investment Research - Mentions: UHS THC EXAS

Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat

a month ago - By: Zacks Investment Research - Mentions: UHS MCK MD

Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses

a month ago - By: Veracyte, Inc.

Veracyte to Participate in Upcoming Investor Conferences

a month ago - By: Benzinga - Mentions: QS FUBO MRVL LMND ...

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday

a month ago - By: Zacks Investment Research - Mentions: AVNS

Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates

a month ago - By: Veracyte, Inc.

Veracyte Announces Third Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

a month ago - By: Veracyte, Inc.

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

a month ago - By: Zacks Investment Research - Mentions: EW PODD PAHC

EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash

a month ago - By: Zacks Investment Research - Mentions: ALGN PODD PAHC

ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash

2 months ago - By: Zacks Investment Research - Mentions: PODD CHE PAHC

CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash

2 months ago - By: Zacks Investment Research - Mentions: PODD PAHC ITGR

ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates

2 months ago - By: Veracyte, Inc.

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

3 months ago - By: Veracyte, Inc.

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

3 months ago - By: Veracyte, Inc.

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

3 months ago - By: Veracyte, Inc.

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

3 months ago - By: Zacks Investment Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

4 months ago - By: Zacks Investment Research

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

4 months ago - By: Veracyte, Inc.

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

4 months ago - By: Veracyte, Inc.

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

4 months ago - By: Zacks Investment Research - Mentions: NEO TEM

Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership

4 months ago - By: Veracyte, Inc.

VERACYTE INC (VCYT) Stock News

VCYT Latest News, Press Relases and Analysis

Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price

PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor

Here's Why You Should Add Cencora Stock to Your Portfolio Now

Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus

EHC Opens New Lake Worth Rehab Hospital to Meet Rising Demand

Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term

TDOC Partners With TytoCare to Expand At-Home Exam Capabilities

Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat

Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat

VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up

Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat

Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses

Veracyte to Participate in Upcoming Investor Conferences

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday

Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates

Veracyte Announces Third Quarter 2025 Financial Results

Earnings Scheduled For November 4, 2025

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash

ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash

CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash

ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test